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Discovery of intramolecular trans-sialidases in
human gut microbiota suggests novel mechanisms
of mucosal adaptation
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Gwenaelle Le Gall1, Willem M. de Vos4,5, Garry L. Taylor2 & Nathalie Juge1
The gastrointestinal mucus layer is colonized by a dense community of microbes catabolizing
dietary and host carbohydrates during their expansion in the gut. Alterations in mucosal
carbohydrate availability impact on the composition of microbial species. Ruminococcus
gnavus is a commensal anaerobe present in the gastrointestinal tract of 490% of humans
and overrepresented in inﬂammatory bowel diseases (IBD). Using a combination of geno-
mics, enzymology and crystallography, we show that the mucin-degrader R. gnavus ATCC
29149 strain produces an intramolecular trans-sialidase (IT-sialidase) that cleaves off terminal
a2-3-linked sialic acid from glycoproteins, releasing 2,7-anhydro-Neu5Ac instead of sialic
acid. Evidence of IT-sialidases in human metagenomes indicates that this enzyme occurs in
healthy subjects but is more prevalent in IBD metagenomes. Our results uncover a previously
unrecognized enzymatic activity in the gut microbiota, which may contribute to the adap-
tation of intestinal bacteria to the mucosal environment in health and disease.
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T
he human gut is populated with microorganisms that play
important roles in health and disease1. The majority of the
gut bacteria are believed to reside within the outer mucus
layer covering the gastrointestinal tract epithelial cells2. Changes
in the balance of different bacteria in our microbiota have been
linked to inﬂammatory bowel diseases (IBD)3,4. There is an
emerging paradigm that mucus is critical to maintain a
homeostatic relationship with our gut microbiota, and that any
deviation from this dynamic interaction has major implications
for health (colitis, colorectal cancer, infections and so on)5–8. For
example, patients suffering from IBD have a disproportionate
representation of mucin degraders, such as Ruminococcus
gnavus9, a common species of gut bacteria found in over 90%
of people10.
Mucins are the most abundant protein in mucus, with a
‘bottle brush’ appearance of sialic acid-capped O-glycan chains
attached to the protein backbone via serine/threonine residues.
Gel-forming mucins are secreted by goblet cells within the
gastrointestinal tract, and represent the interface between the
microbial community and host tissue11. The prominent terminal
locations of host sialic acids have made them one of the
most frequently targeted carbohydrate receptors for pathogen
adherence12. Microbes also express sialidases (also commonly
referred to as neuraminidases), that cleave terminal sialic acid
residues from host sialoglycan substrates. Bacterial sialidases and
their mucosal sialoglycan targets contribute to host–microbe
interactions at every mammalian mucosal surface. Sialidases have
been proposed to promote bacterial survival in mucosal niche
environments via (i) nutritional beneﬁts of sialic acid catabolism,
(ii) unmasking of cryptic host ligands used for adherence,
(iii) participation in bioﬁlm formation and (iv) modulation of
immune function13. Moreover, removal of sialic acid from
sialomucin exposes the glycan moiety that can be more rapidly
catabolized11. A number of sialidase-expressing microbes beneﬁt
from sialic acid hydrolysis via catabolism and utilization of sialic
acid as a carbon source. In bacteria, the genes involved
in sialic acid metabolism are usually found clustered together
forming what is denominated as a Nan cluster. The canonical
cluster nanA/K/E, ﬁrst described for Escherichia coli14 involves
genes encoding the enzymes N-acetylneuraminate lyase (NanA),
kinase (NanK) and N-acteylmannosamine (ManAc) epimerase
(NanE), converting sialic acid (Neu5Ac) into N-acetylgluco-
samine-6-P (GlcNAc-6-P), whereas the genes encoding
NagA (GlcNAc-6-P deacetylase) and NagB (glucosamine-6-P
deaminase) converting GlcNAc-6-P into fructose-6-P, which is a
substrate in the glycolytic pathway, vary in their locations
among the different genomes that encode the Nan cluster15.
An alternative pathway for sialic acid metabolism has later been
discovered in Bacteroides fragilis, relying on the action of an
aldolase (NanL), a novel ManNAc-6-P epimerase (also named
NanE; we refer to this as NanE2 to distinguish it from the E. coli
NanE which we refer to as NanE1) and a hexokinase (RokA),
converting Neu5Ac into GlcNAc-6-P, an intermediate in the
common pathway for aminosugar utilization16. This novel sialic
utilization pathway is deﬁned by the nanLET cluster, where NanT
is a sialic acid transporter16,17. The majority of the bacteria that
encode either of these Nan clusters colonize mucus regions of the
human body, such as the gut, lung, bladder or oral cavity, where
sialic acid is highly abundant and can serve as a source of energy,
carbon, and nitrogen13,18. Interestingly, some bacteria appear to
have only partial packages of enzymes for scavenging host sialic
acids. For example, B. thetaiotaomicron encodes a sialidase and
can release free sialic acid, but lacks the Nan operon required to
consume the liberated monosaccharide and does not appear
capable of consuming hydrolysed sialic acids19. On the other
hand, Salmonella typhimurium and Clostridium difﬁcile encode
the Nan operon but each lacks the sialidase18, and have been
suggested to rely on other sialidase-producing organisms to
acquire this potential nutrient source15,20.
We recently showed that R. gnavus ATCC 29149 encodes a
complete Nan cluster (NanA/K/E) as well as the sialidase required
for sialic acid liberation from host sialylated substrates (NanH)
and a putative sialic acid ABC transporter (Supplementary Fig. 1),
and that the whole cluster was induced when the cells were grown
in the presence of a2-3-linked sialic acid lactose (30SL) or
mucin21. The sialidase and Nan cluster is absent from the genome
of R. gnavus E1, which is unable to grow on mucin as a sole
carbon source21. Taken together, these data indicate that sialic
acid metabolism is key to the ability of R. gnavus strains to utilize
mucin as a nutrient source, which is in agreement with earlier
studies on mucin degradation in the human colon ecosystem22–24.
However, the bacteria (ATCC 29149 and E1) could not grow on
sialic acid as sole carbon source21. Here we functionally and
structurally characterize R. gnavus ATCC 29149 sialidase
(RgNanH), demonstrating that the enzyme is an intramolecular
trans-sialidase (IT-sialidase) producing 2,7-anhydro-Neu5Ac
selectively from a2-3-linked sialic acid substrates, the ﬁrst one
reported in a gut commensal microbe suggesting an unprecedented
mechanism underpinning adaptation of gut bacteria to the
sialylated-rich mucosal environment.
Results
RgNanH produces 2,7-anhydro-Neu5Ac from a2-3-linked Neu5Ac.
To determine the substrate speciﬁcity of R. gnavus ATCC
29149 sialidase (RgNanH), the full-length gene was hetero-
logously expressed in E. coli and the recombinant enzyme was
puriﬁed to homogeneity. The enzymatic activity of the recombi-
nant protein was ﬁrst assessed using the synthetic ﬂuorescent
substrate, 20-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid
(4MU-Neu5Ac; Table 1). RgNanH displayed a pH optimum of
6.5 and a broad temperature optimum ranging from 25 to 40 C
(Supplementary Fig. 2), consistent with the environment of the
human gut. These conditions (pH 6.5, 37 C) were used to determine
the kinetic parameters of RgNanH against the synthetic substrates
4MU-Neu5Ac and 2-O-(p-nitrophenyl)-a-D-N-acetylneuraminic
Table 1 | Kinetic parameters of RgNanH with sialylated substrates.
Substrate Vmax (lMmin 1) kcat (min 1) KM (mM) kcat/KM (min 1 mM 1) Ki (mM)
MU-Neu5Ac 1.37±0.23 6.21 103 0.59±0.17 1.05 104 2.37±0.65
PNP-Neu5Ac ND o152* 425w 6.07 103 ND
30SL 5.66 10 2±0.57 10 2 25.70 oo0.1w 442.57 102* 0.76±0.23
ND, not detectable.
The s.e.m. is shown.
*Parameter calculated using estimated value.
wEstimated value.
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acid (PNP-Neu5Ac; Fig. 1a,b and Table 1). RgNanH showed
6.21 103min 1 kcat and 0.59mM KM against 4MU-Neu5Ac,
but a high KM and low activity against PNP-Neu5Ac.
The activity of RgNanH against 4MU-Neu5Ac was further
tested in the presence of a range of known neuraminidase
inhibitors (Supplementary Fig. 3). RgNanH showed moderate
inhibition by 2-deoxy-2, 3-didehydro-D-N-acetylneuraminic
acid (Neu5Ac2en; IC50 of 1.4mM) and a lower inhibition
by its derivative 4-guanidino-Neu5Ac2en (zanamivir; IC50 of
11.89mM). Oseltamivir carboxylate (OC) was substantially more
effective with an IC50 of 30mM (Fig. 1c and Table 2). Siastatin B
was the best inhibitor of RgNanH with an IC50 of 5 mM (Fig. 1c
and Table 2). RgNanH was not inhibited by lactose (Lac) or
Neu5Ac (Supplementary Fig. 4).
Preference of RgNanH in cleaving either a2-3- or a2-6-linked
sialic acid was assessed by incubation of the enzyme with 30SL
and 60-sialyllactose (60SL), which contain a2-3- and a2-6-linked
sialic acid, respectively (Fig. 1d and Table 3). The enzyme showed
a KM for 30SL below detection limit, indicative of a very high
afﬁnity of the enzyme for this substrate and an estimated kcat of
25.7min 1, whereas no enzymatic activity was observed in
presence of 60SL, demonstrating exclusive substrate speciﬁcity of
the enzyme for a2-3 linkages. The higher activity (kcat) of the
enzyme for 4MU-Neu5Ac compared with 30SL may be due to
MU acting as a better leaving group. The enzyme showed
substrate inhibition with both synthetic and natural substrates
(Fig. 1a,d and Table 1), with a lower Ki for the 30SL (0.76mM),
compared with 4MU-Neu5Ac (2.37mM). In contrast, two
sialidases AkmNan0625 and AkmNan1835 from Akkermansia
muciniphila, used as controls, were active against both 30SL
and 60SL (Fig. 1a,b). The substrate and product speciﬁcity
of the enzymes were further monitored by HPAEC-PAD
(high-performance anion exchange chromatography-pulsed
amperometric detection; Fig. 2 and Table 3) using substrates
ranging from the monosaccharide galactose to the branched
trisaccharide Lewis X conjugated to sialic acid with either a2-3
or a2-6 linkages. While the A. muciniphila sialidases released
Neu5Ac from all substrates tested, RgNanH activity was only
observed for a2-3-linked sialyl-oligosaccharides, as observed by
the disappearance of the substrate peak and the appearance of a
lower-molecular weight peak that may correspond to the
desialylated substrate. However, no free Neu5Ac was observed
from the action of RgNanH.
The products of the reaction were thus further monitored by
1H nuclear magnetic resonance (NMR). The spectra clearly
showed the presence of two 1H NMR signals at 4.56 and
4.45 p.p.m. (Fig. 3). These peaks are characteristic of 2,7-anhydro-
a-N-acetylneuraminic acid (2,7-anhydro-Neu5Ac) and arise from
the protons in positions 6 and 7 (Fig. 3a). Peaks corresponding
to 2,7-anhydro-Neu5Ac were observed when RgNanH was
incubated in presence of 4MU-Neu5Ac (Fig. 3a) or 30SL
(Fig. 3b). No changes in the peaks corresponding to 2,7-anhydro-
Neu5Ac were observed after incubation of RgNanH with sialylated
substrates for up to 24 h at 37 C, and no signal corresponding to
free sialic acid could be detected, as also observed with
the HPAEC-PAD experiments, indicating no spontaneous
conversion of 2,7-anhydro-Neu5Ac to Neu5Ac. Conversely, there
was no evidence of spontaneous conversion of Neu5Ac to
2,7-anhydro-Neu5Ac by NMR under the experimental conditions
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Figure 1 | Kinetic analysis of the hydrolysis of sialylated substrates by RgNanH in presence or absence of inhibitors. Substrate (a) 4MU-Neu5Ac or
(b) PNP-Neu5Ac was incubated with RgNanH (0.22mM and 0.43 nM, respectively) at 37 C, pH 6.5 and the release of product measured using
a plate reader. (c) Inhibition of RgNanH (1.00 nM) incubated with 4MU-Neu5Ac (0.51mM) by zanamivir (K), Neu5Ac2en (’), siastatin B (m) and OC
(~), the rates are normalized to a % of the uninhibited rate. [I] is the inhibitor concentration. (d) 30SL was incubated with RgNanH (2.25 nM) and the
release of product measured by HPAEC-PAD. Experiments were done at least in duplicate (usually triplicate) and the error bars show the s.e.m.
Table 2 | Effect of neuraminidase inhibitors on RgNanH
activity.
Inhibitor LogIC50 IC50 (mM)
Zanamivir 1.08±0.07 11.89
Neu5Ac2en 0.15±0.04 1.41
Siastatin B  2.31±0.02 4.87 10 3
Oseltamivir carboxylate  1.53±0.02 2.96 10 2
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tested. The signals of 2,7-anhydro-Neu5Ac and their chemical
shifts are shown in Supplementary Table 1. This product was
absent in control experiments using A. muciniphila sialidases
(AkmNan0625 and AkmNan1835) or in absence of enzyme,
conﬁrming the speciﬁcity of the enzymatic reaction
(Supplementary Fig. 5). These data indicate that RgNanH
produces 2,7-anhydro-Neu5Ac rather than Neu5Ac from sialy-
lated oligosaccharides.
The ability of RgNanH to hydrolyse sialic acid from
glycoproteins was investigated by incubation of the enzyme with
human a-1-acid glycoprotein (AGP) and fetuin (Fet) both of
which are known to contain a2-3 sialyl linkages, while asialo-Fet
was also included as a control. RgNanH showed activity against
AGP and Fet, as monitored by 1H NMR with the detection of
peaks corresponding to 2,7-anhydro-Neu5Ac but not Neu5Ac,
whereas no change was observed in the control reaction with
asialo-Fet in presence or absence of RgNanH (Supplementary
Fig. 6).
Taken together, these data demonstrate that RgNanH encodes
an IT-sialidase, producing 2,7-anhydro-Neu5Ac selectively from
a2-3-linked sialic acid substrates.
RgNanH shares structural homology with IT-sialidases.
RgNanH sequence encodes a three domain modular protein with
an N-terminal lectin-like domain (L-domain) classiﬁed as a
member of the carbohydrate-binding module family 40 (CBM40;
www.cazy.org), a catalytic domain (N-domain) classiﬁed as a
member of the glycoside hydrolase family 33 (GH33; www.
cazy.org) and a domain inserted into the catalytic domain
(I-domain). To date, only two enzymes with IT-sialidase activity
have been reported, NanL from Macrobdella decora (North
American leech)25 and NanB from the human pathogen
Streptococcus pneumoniae26. RgNanH shares B75% and B42%
sequence identity over the whole protein length with NanL and
NanB, respectively, and the same multidomain architecture.
Homology is greatest in the catalytic domain (excluding the
I-domain), showing B81% and B46% identity with NanL and
NanB, respectively. The CBM40 L-domain shares B67% and
B30% identity, and the I-domain shares 64% and 43%, both
respective to NanL and NanB.
To investigate the structural basis for the IT-sialidase
reaction by RgNanH, we determined the crystal structure of
RgNanH catalytic domain, free and in complex with the ligands
Table 3 | Speciﬁcity of RgNanH and AkmNan0625 and 1,835 against 30- and 60-linked sialyl-oligosaccharides.
Substrate (common name) Systematic name Activity*
RgNanH AkmNan0625 and AkmNan1835
30-Sialyllactose Neu5Ac-a-2-3-Gal-b-1-4-Glc þ þ
30-Sialyl-3-fucosyllactose Neu5Ac-a-2-3-Gal-b1-4-[Fuc-a-1-3]-Glc þ þ
30-a-Sialyl-N-acetyllactosamine Neu5Ac-a-2-3-Gal-b-1-4-GlcNAc þ þ
30-Sialyl Lewis X Neu5Ac-a-2-3-Gal-b-1-4-[Fuc-a-1-3]-GlcNAc þ þ
30-Sialyl Lewis X methyl glycoside Neu5Ac-a-2-3-Gal-b-1-4-[Fuc-a-1-3]-GlcNAc-b-OMe þ þ
30-Sialylgalactose Neu5Ac-a-2-3-Gal þ þ
60-Sialyllactose Neu5Ac-a-2-6-Gal-b1-4-Glc  þ
60-a-Sialyl-N-acetyllactosamine Neu5Ac-a-2-6-Gal-b-1-4-GlcNAc  þ
60-Sialylgalactose Neu5Ac-a-2-6-Gal  þ
-OMe, -O-methyl group
*Activity was deﬁned as disappearance of the substrate peak and appearance of a lower-molecular weight peak, which could correspond to the desialylated substrate.
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Figure 2 | Speciﬁcity of RgNanH towards sialylated oligosaccharides. The enzymes were incubated with sialylated substrates at 37 C, pH 6.5, overnight
and the reaction products were analysed by HPAEC-PAD. Control reactions without enzyme were also performed. The injection peak is marked (inj).
Glycerol (gly) was also present in AkmNan0625. (a) Standards (Lac, Neu5Ac, 30SL and 60SL), (b) 30SL, (c) 60SL and (d) 3’-a-sialyl-N-acetyllactosamine
(30SLacNAc). AkmNan1835 has a similar proﬁle to AkmNan0635.
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identiﬁed above. RgNanH catalytic domain (residues 243–723)
was heterologously expressed and puriﬁed, and the crystal
structure of the N-domain with the inserted I-domain
(NI-domain) was solved to a maximum resolution of 1.71 Å
(Table 4). As shown in Fig. 4a, the N-domain adopts the
canonical sialidase six-bladed b-propeller fold, which is shared
with NanL27 (PDB 2SLI) and NanB28 (PDB 2VW0). The
N-domain contains four asparagine boxes, one in each of the
ﬁrst four b-propeller blades. These are common structural
motifs in bacterial sialidases and form b-hairpin loops between
b-strands three and four of a b-propeller blade, providing
blade-to-blade interactions29. There is an extended b-hairpin
loop in the equivalent position in blade ﬁve. The I-domain is
formed by a loop extended from between two blades of the
propeller and is primarily comprised of b-strands (Fig. 4a). The
enzyme surface displays a signiﬁcant charge bias, with the
active site face being generally positive and the opposite face
substantially negative (Fig. 4b). Soaking of the NI-domain
crystals with 30SL resulted in substrate turnover, leading to a
protein ligand complex with 2,7-anhydro-Neu5Ac bound into
the active site (Fig. 5). RgNanH active site presents the classical
features of bacterial sialidases, shared by hydrolytic and trans-
sialidases (Fig. 5a). These include an arginine triad formed by
Arg257, Arg637 and Arg575; a catalytic pair formed by Glu559
and Tyr677; a general acid base, Asp282; and a pocket to
accommodate the N-acetyl group. As shown in Fig. 5a,
the arginine triad forms electrostatic interactions with the
2,7-anhydro-Neu5Ac carboxylate group, orientating the ligand
in the active site. Asp282 forms hydrogen bonds with the newly
formed ethylene glycol group. The ligand N-acetyl group sits in
a pocket between Ser364 and Ile338 with the amine providing
hydrogen-bonding interactions to Asp339, and Glu559 and
Tyr525 via a buried water molecule. The carbonyl group of the
N-acetyl functional group may also interact with Asp282 via a
water molecule.
The formation of the intramolecular sialosyl linkage speciﬁc to
IT-sialidases has been proposed to be owing to the positioning of
a threonine underneath the glycerol group of the sialic acid
substrate, forcing it into an axial position from which it can attack
the ring carbon C2 (ref. 30). In RgNanH, this mechanism would
appear to be conserved through Thr557. Furthermore, there is a
hydrophobic stack formed by Tyr607 and Trp698 in front of the
active site (Fig. 5a). This feature is likely to be responsible for the
speciﬁcity of IT-sialidases for a2-3-linked substrates and also for
creating a generally hydrophobic region of the active site,
favouring nucleophilic attack by the glycerol group rather than
an incoming water molecule30.
To gain further insights into the inhibition proﬁle of this
enzyme, crystal structures of RgNanH in complex with inhibitors
tested enzymatically were investigated. Complexes with Neu5A-
c2en, OC and siastatin B, bound in the active site, were solved to
2.00, 2.01 and 1.94Å, respectively (Table 4, Fig. 5b–d and
Supplementary Fig. 7). It was not possible to obtain a crystal
structure of zanamivir in complex with the enzyme, probably
owing to its low afﬁnity for RgNanH (IC50 of B12mM).
Neu5Ac2en (IC50 of 1.4mM) bound to RgNanH active site in a
half-boat conformation, planar around the C2 (Fig. 5b). Most
protein–inhibitor interactions were similar to those observed with
2,7-anhydro-Neu5Ac, including the carboxylic acid group to the
arginine triad, hydroxyl O4 to Arg276 and Asp339, and those
made by the N-acetyl group. There is a hydrogen bond between
the ﬁrst hydroxyl of the glycerol group (O7) and Asp282 (Fig. 5b),
which is similar to the interaction observed between Asp282 and
the ethylene glycol group of 2,7-anhydro-Neu5Ac. OC (IC50 of
B30 mM) is a substantially more potent inhibitor of RgNanH
than Neu5Ac2en. Based on a cyclohexene scaffold rather than
b 3′SL 4.0–5.3 p.p.m.a MU-Neu5Ac 4.0–5.3 p.p.m.
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Figure 3 | H1 NMR analysis of RgNanH reaction products in presence of 4MU-Neu5Ac or 30SL. RgNanH was incubated with (a) 4MU-Neu5Ac or
(b) 30SL at 37 C, pH 6.5, overnight and the reaction mixture analysed by H1 NMR. Control reactions without enzyme (‘—’, lower trace) were carried out in
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didehydropyran, OC has an amine at position C4 in comparison
with the hydroxyl of Neu5Ac2en and a pentyl ether group in
place of the glycerol group (Supplementary Fig. 3). The C4 amine
formed hydrogen bonds with RgNanH Asp282 and Asp339
(Fig. 5c). OC is shifted out of the active site by B0.6 Å, as
compared with Neu5Ac2en, which may be due to repulsive effects
between the inhibitor amino group and Arg276. The ether oxygen
of the pentyl ether functional group may interact with Asp282 via
a water molecule.
Siastatin B (IC50 of B5 mM) was the most potent inhibitor
tested. Siastatin B is based on an iminosugar scaffold with
carboxylic acid, hydroxyl and N-acetyl functional groups at
equivalent positions to Neu5Ac, an additional hydroxyl group is
present at position 3 (Supplementary Fig. 3). The siastatin B
inhibitor bound to the active site in a chair conformation
(Fig. 5d). Like Neu5Ac2en, the carboxylic acid group of siastatin
B interacts with the arginine triad, and the O4 hydroxyl with
Arg276 and Asp339. Furthermore, the axial C3 hydroxyl of
siastatin B formed hydrogen bonds to Asp282 and Arg257 of the
arginine triad. Asp282 may interact with the carbonyl of the
ligand N-acetyl group via a water molecule. This was also
observed in the 2,7-anhydro-Neu5Ac complex. Both the nitrogen
of the carbohydrate ring and of the N-acetyl group formed
hydrogen bonds to a buried water molecule, resulting in a more
extensive hydrogen-bonding network in this region than seen in
the Neu5Ac2en and OC complexes.
IT-sialidases are overrepresented in IBD gut metagenomes. To
assess the prevalence of IT-sialidase-positive bacteria across the
human gut microbiota, initial assemblies of sequenced metagen-
omes of human stool samples from 99 healthy subjects and 25
IBD patients10 were examined for the presence of IT-sialidases.
We used proﬁle hidden Markov models (pHMMs) to search the
protein sequences resulting from translating the assembled
coding sequences (14.1 million in all, with a mean length of
637 bp). All subjects’ metagenomes were positive for a sialidase
gene (mean 30 coding sequences per subject). The IT-sialidase
was more scarcely detected, being present in 10.5% of all subjects,
a
b
180°
90°
Figure 4 | RgNanH catalytic domain bound to Neu5Ac2en. (a) Cartoon
representation of the RgNanH NI-domain, the catalytic N-domain is shown
with green secondary structure features and the inserted I-domain is shown
with red secondary structure features. Neu5Ac2en is shown bound in the
active site. (b) The RgNanH NI-domain with an electrostatic surface
applied. Neu5Ac2en is shown bound in the active site.
Table 4 | Data collection and reﬁnement statistics*.
2,7-Anhydro-Neu5Ac Neu5Ac2en Oseltamivir carboxylate Siastatin B
PDB identiﬁer 4X4A 4X47 4X49 4X6K
Data collection
Space group R3 R3 R3 R3
Cell dimensions
a, b, c (Å) 99.26, 99.26, 130.60 101.31, 101.31, 131.94 101.10, 101.10, 131.54 99.11, 99.11, 131.71
a, b, g () 90.00, 90.00, 120.00 90.00, 90.00, 120.00 90.00, 90.00, 120.00 90.00, 90.00, 120.00
Resolution (Å) 92.54–1.71 (1.74–1.71) 73.05–2.00 (2.03–2.00) 72.88–2.01 (2.04–2.01) 71.91–1.94 (1.97–1.94)
Rmerge 0.049 (0.421) 0.064 (0.490) 0.068 (0.499) 0.066 (0.458)
I/sI 41.72 (3.09) 25.42 (3.17) 20.32 (2.93) 25.30 (3.88)
Completeness (%) 92.90 (53.00) 99.5 (99.7) 98.3(97.20) 98.30 (94.41)
Redundancy 4.2 (2.4) 2.9 (2.6) 2.7 (2.4) 3.1 (3.0)
Reﬁnement
Resolution (Å) 92.54–1.71 (1.76–1.71) 73.05–2.00 (2.05–2.00) 72.88–2.01 (2.06–2.01) 71.91–1.94 (2.00–1.94)
No. of reﬂections 51,820 32,166 30,874 32,952
Rwork/Rfree 0.143/0.188 (0.761) 0.215/0.273 (0.778) 0.184/0.245 (0.751) 0.177/0.225 (0.79)
No. of atoms 4,411 4,080 4,272 4,281
Protein 3,836 3,820 3,803 3,798
Ligand/ion 46 25 54 18
Water 529 235 415 465
B-factors
Protein 29.199 40.950 30.786 26.562
Ligand/ion 37.084 39.018 34.223 20.960
Water 44.571 43.514 38.415 35.491
R.m.s.d.
Bond lengths (Å) 0.019 0.016 0.016 0.019
Bond angles () 1.891 1.787 1.802 1.923
R.m.s.d., root mean squared deviation.
*Values in parentheses are for the highest-resolution shell. One crystal was used for each structure.
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with a mean of 1.5 sequences per positive subject. However, of the
non-IBD subjects, 8.1% were positive for IT-sialidase in contrast
to 20% of the smaller group of IBD subjects. In the two groups,
respectively, 1 in 830,000 and 1 in 422,000 of all the coding
sequences were identiﬁed as IT-sialidase (Table 5). These data are
consistent with an overrepresentation of IT-sialidases in IBD
patients.
To further investigate the nature of the bacteria species
possessing the IT-sialidase-encoding gene (RgNanH), in addition
to the known Nan clusters, we performed a bioinformatics
analysis using the same pHMMs (see Methods section for details).
We found that the genomes of 488 bacterial strains (6% of the
8,126 analysed), representing 44 species, had IT-sialidase hits, of
which 94% (457 strains), representing 32 species, tested positive
for potential NanA-, NanK- and NanE1-encoding genes within a
cluster spanning up to 15 contiguous gene loci. These strains
represent 18% of all genomes with this cluster. A further six
IT-sialidase-positive species (all with genomes in draft form)
matched these three genes but not in a cluster. Four of the
IT-sialidase species were positive for homologues of the
NanL, NanE2, RokA components of the B. fragilis pathway
(in total, 1,796 strains possessed these components). All strains
positive for the B. fragilis components lacked a match to NanE1
(Supplementary Table 2). A total of 3,427 strains were found
positive for either the NanL/RokA/NanE2 set of genes or the
NanA/K/E1 cluster or both (if the latter genes are permitted to be
present but not necessarily in a cluster then this rises to 4,127). Of
these, 460 (13%) have an IT-sialidase gene. The CBM40 domain
was associated with 75% of the IT-sialidases. Interestingly the IT-
sialidase-positive strains from species known to occur in the
human gut seemed restricted to Firmicutes, in particular,
Clostridiales and Lactobacillales (Supplementary Table 2).
Discussion
Sialidases are a large group of enzymes that catalyse the cleavage
of terminal sialic acids from complex carbohydrates on
glycoproteins or glycolipids. Based on their substrate speciﬁcity
and catalytic mechanism, sialidases can be separated into three
different classes. Hydrolytic sialidases cleave the glycosidic bond
of terminal sialic acids and release free sialic acid, whereas trans-
sialidases transfer the cleaved sialic acid to other glycoconjugates;
according to the Enzyme Commission, both classes belong to
exo-a-sialidases (EC 3.2.1.18). Hydrolytic sialidases usually have
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Figure 5 | The RgNanH active site bound in complex with 2,7-anhydroNeu5Ac and sialidase inhibitors. Cartoon representation of the RgNanH active site
complexed with (a) 2,7-anhydro-Neu5Ac, (b) Neu5Ac2en, (c) OC and (d) siastatin B. Bound ligands are shown in orange with the unbiased Fo-Fc
map contoured to s¼ 3. Relevant residues are highlighted as sticks and water molecules as red spheres. Black dashed lines represent the hydrogen-bonding
network. The lower panel is related to the upper panel by a rotation along the z axis of 90 followed by a rotation along the x axis of 45.
Table 5 | Presence of IT-sialidase in the MetaHit human samples.
Subject
group
No. of
samples
Mean sequences
per sample
Mean bp
per sequence
Protein
domain
% Hit
sequences
Positive samples (that is, with
Z 1 hit sequence)
% Positive
samples
Mean hit
sequences per
sample
IBD¼N 99 117,359.99 636.90 Sialidase 0.0259% 99 100 30.44
I-domain 0.0001% 8 8 0.14
IBD¼Y 25 101,351.28 637.90 Sialidase 0.0268% 25 100 27.12
I-domain 0.0002% 5 20 0.24
IBD, inﬂammatory bowel disease; N, negative; Y, yes.
Incidence of hits in the HMMER3 search for the sialidase and I-domains in coding sequences from the MetaHIT study10. Each sample consists of assembled coding sequences from the gut metagenome
of a single subject designated as N or Y for IBD according to that study.
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wide substrate speciﬁcity and cleave a2-3-, a2-6- and a2-8-linked
terminal sialic acids, whereas trans-sialidases have a preference
for a2-3-linked substrates. The third class is the IT-sialidase (EC
4.2.2.15) that is strictly speciﬁc for a2-3-linked sialic acids and
produces 2,7-anhydro-Neu5Ac (ref. 31). To date, only NanL from
M. decora and NanB from S. pneumoniae have been assigned to
this third class25,26. These enzymes are unique in that they
catalyse an IT-reaction in which the O7-hydroxyl group of the
bound sialic acid glycerol group attacks the positively charged C2
atom of the oxocarbenium intermediate. This altered reaction
pathway leads to the release of 2,7-anhydro-Neu5Ac instead of
Neu5Ac, the reaction product for hydrolytic sialidases. Here we
have shown that RgNanH is a novel member of this class, the ﬁrst
one identiﬁed and characterized in members of the human gut
microbiota. The enzyme showed strict speciﬁcity towards a2-3
glycosidic substrate linkages as tested by HPAEC and 1H NMR
using a range of natural substrates from disaccharides to
branched tetrasaccharides. The production of 2,7-anhydro-
Neu5Ac in the reaction with 30SL and synthetic substrates
4MU-Neu5Ac and PNP-Neu5Ac conﬁrmed that RgNanH is an
IT-sialidase. Furthermore, human a-1-AGP and Fet were both
substrates of RgNanH, in agreement with the presence of a2-3
sialic acid linkages in these proteins; Neu5Ac-a2-6-Gal, Neu5Ac-
a2-3-Gal as well as Lewis X epitopes are found in AGP32, whereas
Fet also contains sialylated a2-6-Gal and a2-3-Gal epitopes33.
The RgNanH crystal structures showed active site features
associated with the IT-sialidase class. Of particular importance
is the conservation of Thr557, which seems to sterically force the
substrate glycerol group into a position from where it can attack
the C2 atom, and of the Tyr607 and Trp698 hydrophobic stack,
proposed to be responsible for the observed substrate speciﬁcity
and also the maintenance of a desolvated active site promoting
nucleophilic attack by the glycerol group27.
RgNanH displayed activity against all a2-3-linked substrates
tested. So far, the active site has been considered to be the pocket
accommodating the terminal sialic acid residue of the substrate.
However, the reaction rate is greatly inﬂuenced by the leaving
aglycone, as shown by the variation in KM and efﬁciency of
cleavage (kcat/KM) between 4MU-Neu5Ac and PNP-Neu5Ac,
even though both the ﬂuorophore and chromophore have similar
leaving abilities (pKa 7.79 and 7.23, respectively). 30SL also
displays much tighter apparent afﬁnity than the synthetic
substrates. Similar results have also been observed in other
sialidases. For example, NanC, an a2-3-linkage-speciﬁc sialidase
from S. pneumoniae that shares 42% identity with RgNanH,
shows a preference to LacNAc- compared with Lac-based
substrates, and demonstrates reduced activity towards fucosylated
glycans34. In the Trypanasoma cruzi trans-sialidase, 4MU-
Neu5Ac is a much poorer substrate than 30SL, and molecular
dynamics simulations suggest that MU, the 4MU-Neu5Ac leaving
group, is unable to form the same favourable interactions as
Lac35. It is probable that additional interactions between RgNanH
and the aglycone may tune the enzyme speciﬁcity to complex
substrates. Furthermore, both 30SL and 4MU-Neu5Ac showed
substrate inhibition, suggesting a potential mechanism for
regulation of this enzyme activity. To the best of our
knowledge, substrate inhibition has not been reported for other
sialidases, but there is a paucity of kinetic data, particularly for
IT-sialidases.
Siastatin B was the most effective inhibitor of RgNanH with an
IC50 of B5 mM, compared with zanamivir (IC50 of B12mM),
Neu5Ac2en (IC50 of 1.4mM) and OC (IC50 of 30 mM). Our
crystal structures of RgNanH inhibitor complexes, including the
ﬁrst published structure of a complex between siastatin B and a
sialidase, provide a structural explanation for the differences in
inhibition between the chemical inhibitors tested. Neu5Ac2en, an
analogue of Neu5Ac dehydrated at C2, is a general sialidase
inhibitor that inhibits both viral and bacterial sialidases36,37,
including the hydrolytic sialidase expressed by B. thetaiotaomicron38.
It has been proposed that Neu5Ac2en is a poor inhibitor and
transition state mimic of IT-sialidases because the glycerol group
is constrained by the C2¼C3 bond and is unable to occupy the
axial position required for catalysis27, as also seen in the
RgNanH–Neu5Ac2en complex (Fig. 5b). OC and zanamivir are
variants of Neu5Ac2en originally designed to improve inhibition
of the viral neuraminidase from inﬂuenza. In the case of OC,
these modiﬁcations led to an improvement in inhibition of
RgNanH by B50-fold (IC50: 1.4mM to 30 mM). This is likely
owing to enhanced interactions from the C4 amine group, as seen
in the complex structure (Fig. 5c). In contrast, Neu5Ac2en makes
a direct hydrogen bond to Asp282 via the hydroxyl O7. This
interaction is not present in the complex with OC, although there
may be a water-mediated interaction from Asp282 to the ether
oxygen. In viral neuraminidases, and hydrolytic sialidases such as
NanA from S. pneumoniae, there are substantial hydrophobic
interactions with the pentyl ether functional group of OC36,37;
these interactions are not present in RgNanH, which may explain
why OC is less potent towards IT-sialidase. Zanamivir was a very
poor inhibitor of RgNanH, which is not surprising since the
inhibitor has a much bulkier guanidino substitution at the C4
position, which, based on the above complex crystal structures,
would clash with Arg276 and Asp339. The complex between
siastatin B and RgNanH suggests a structural explanation for its
effective inhibition of the enzyme (Fig. 5d). Siastatin B adopts a
chair conformation rather than the more planar, half-boat
Neu5Ac2en conformation. Furthermore, in comparison with
Neu5Ac2en and OC, siastatin B makes a more extensive
hydrogen-bonding network underneath the ligand via the
buried water. Siastatin B also makes extensive interactions
through the O3 hydroxyl to Asp282 and Arg257. Finally,
although both Neu5Ac2en and siastatin B form hydrogen
bonds to Asp282 (Neu5Ac2en via the glycerol group), siastatin
B achieves such interaction without paying the entropic penalty
required to avoid a steric clash between the glycerol group and
Thr557. Overall, the inhibitor data showed considerable
differences between RgNanH and viral neuraminidases, whether
this is due to the nature of the enzyme, IT-sialidase versus
hydrolytic sialidase, or due to its bacterial versus viral origin
remain to be demonstrated.
Our biochemical assays highlighted differences in sialylated
substrate speciﬁcity between R. gnavus and other gut mucin-
degrading bacteria, such as A. muciniphila, which is a dedicated
mucus utilizer that has found to increase intestinal permeability
in mice39,40. Many enteric commensal and pathogenic bacteria
can utilize sialic acids from their hosts owing to the presence of a
Nan cluster18,41, but not all have the ability to release sialic acid
from glycoproteins. Among gastrointestinal commensals,
Bacteroidetes species are found at high abundance and many of
them express sialidases in culture42. However, some bacteria, such
as B. thetaiotaomicron encode the sialidase required to cleave and
release this terminal sugar from the mucosal glycoconjugates, but
do not encode a sialic acid lyase/aldolase homologue and lack the
catabolic pathway (that is, the Nan clusters) required to consume
the liberated monosaccharide. Presumably, the release of sialic
acids allows B. thetaiotaomicron to access highly coveted
underlying carbohydrates in the mucus43,44. B. fragilis or E. coli
on the other hand possesses the complete pathway of sialic acid
catabolism including the hydrolytic sialidase gene16,45. Both
B. fragilis and E. coli catabolic genes are upregulated in response
to available free sialic acid45. A recent study reported that mice
monoassociated with B. thetaiotaomicron exhibited a signiﬁcantly
higher concentration of free Neu5Ac versus germ-free mice,
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consistent with the ability of B. thetaiotaomicron to liberate, but
not consume, the monosaccharide, whereas colonization of mice
with B. fragilis, which is able to catabolize Neu5Ac, did not result
in increased free sialic acid20. This repartition of free sialic acid in
the gut is important as some bacterial pathogens such as
S. typhimurium and C. difﬁcile do not encode sialidases and
thus rely on the sialic acid liberated by the resident microbiota
to expand in the mucosal environment46,47. This cross-
feeding activity has also been reported between members of
Biﬁdobacteria, for example, Biﬁdobacterium breve UCC2003
(containing a functional Nan cluster for sialic utilization) can
utilize sialic acid released by the sialidase activity of B. biﬁdum
PRL2010 (ref. 48). R. gnavus ATCC 29149 is different to the
above as it possesses the complete Nan cluster and an IT-
sialidase-producing 2,7-anhydro-Neu5Ac instead of Neu5Ac
from a2-3-linked sialic acid substrates, which is consistent with
the bacteria ability to grow on 30SL but not on sialic acid, Lac or
60SL and the induced expression of the Nan cluster and RgNanH
on 30SL (ref. 21). Our bioinformatics analysis revealed that the
presence of IT-sialidases is shared by other members of the gut
microbiota, in particular Blautia hansenii and R. torques, all 10
strains of C. perfringens with available genome data, C. sp. 7 2 43
FAA, C. celatum, C. nexile and C. spiroforme, three unclassiﬁed
Lachnospiraceae, 4100 strains of S. agalactiae and three of the
genome-sequenced publicly available Lactobacillus salivarius
strains. Of 1,165 strains testing positive for a sialidase and the
Nan clusters, 40% (457 strains) tested positive speciﬁcally for the
IT-sialidase (the remainder matched the sialidase domain but
lacked the I-domain). The detection of IT-sialidase homologues
in at least 11% of gut metagenomes of a population of diseased
and healthy humans is in line with this analysis, showing that this
enzyme is widespread across gut bacteria, especially in Firmicutes.
The speciﬁc niche colonization of these bacteria may reﬂect
an adaptation to particular mucus glycosylation proﬁles. The
R. gnavus mucin-utilization enzymatic proﬁle, which is mainly
based on the release and use of sialic acid to support growth21,
appears particularly well adapted to digest mucin with short
chains terminated by sialic acid, such as sialyl-Tn-antigen, which
is found in higher proportion in IBD patients49. On the contrary,
other mucin degraders such as A. muciniphila or B. thetaiotaomicron
cannot utilize sialic acid as carbon source, so will be
disadvantaged by the mucin glycosylation proﬁle of IBD
patients, while more adapted to utilize complex mucin glycan
structures50 that require the synergistic action of several glycoside
hydrolases51. Furthermore, the IT-sialidase may provide gut
microbes such as R. gnavus ATCC 29149 with an additional
competitive nutritional advantage, allowing the bacteria to thrive
within mucosal environments by scavenging sialic acid from host
mucus in a form, 2,7-anhydro-Neu5Ac, which may not be readily
accessible to other members of the gut microbiota, thus limiting
loss to other microbiota residents and/or exploitation by enteric
pathogens. This ‘selﬁsh’ model of mucosal glycan utilization
could contribute to the disproportionate representation of
R. gnavus reported in ulcerative colitis and Crohn’s disease
patients9,52,53. It is interesting to note that R. torques, predicted to
encode an IT-sialidase, is also a mucin degrader frequently
associated with conditions such as intestinal disorders, including
IBD and irritable bowel syndrome, and other health problems
such as autism spectrum disorders9,53–55. This contrasts with the
sialidases AkmNan0625 and AkmNan1835 from the commensal
mucin degrader A. muciniphila, the amount of which has
shown to be inversely correlated with that of R. torques in
ulcerative colitis and Crohn’s disease mucosa9,47. Furthermore,
the overrepresentation of IT-sialidase-encoding genes in the
metagenome of IBD patients suggests that IT-sialidase-encoding
bacteria may be particularly adapted to this particular mucosal
niche. Future studies in these systems should deﬁne how
IT-sialidase action on speciﬁc sialoglycans inﬂuences pathological,
commensal and/or symbiotic host–microbe relationships within
the complex sialoglycan-rich environment of the human gut.
Methods
Reagents. All chemicals were obtained from Sigma (St Louis, USA) unless
otherwise stated. The A. muciniphila sialidases, termed here AkmNan0625 and
AkmNan1835, were obtained by His-Tag overexpression of their genes
(Amuc_0625 and Amuc_1835, respectively)56 in E. coli BL21(DE3) and subsequent
puriﬁcation to homogeneity by immobilized metal afﬁnity chromatography as
described below. The sialylated oligosaccharides and OC were obtained from
Carbosynth (Berks, UK).
Cloning, expression and puriﬁcation of full-length sialidases. The full-length
RgNanH sialidase excluding the signal sequence (residues 1–25) was cloned into
the pOPINF expression system57, introducing an His-tag at the N terminus. The
primers used were as follows: forward 50-AAGTTCTGTTTCAGGGCCCGCAAG
AGGCCCAGACAGAT-30 , reverse 50-ATGGTCTAGAAAGCTTTATGGTTGAAC
TTTCAGTTCATC-30 . DNA manipulation was carried out in E. coli XL1 Blue
(New England BioLabs, Boston, USA). Sequences were veriﬁed by DNA sequencing
by Euroﬁns (Ebersberg, Germany). E. coli BL21 (New England BioLabs) cells were
transformed with the recombinant plasmid harbouring the sialidase gene according
to manufacturer’s instructions. For small-scale expression, the recombinant cells
were grown to an OD600 of 0.6 in Luria-Bertani Broth (10–50ml) and then induced
with 1mM isopropyl b-D-1-thiogalactopyranoside overnight at 22 C. The cells
were harvested by centrifugation at 10,000g for 20min. Large-scale expression (1 l)
was carried out in ‘Terriﬁc Broth Base with Trace Elements’ autoinduction media
(ForMedium, Dundee, UK) growing cells for 3 h at 37 C and then induced at
16 C for 48 h. The cells were harvested by centrifugation at 10,000g for
20min. The His-tagged proteins were puriﬁed by immobilized metal afﬁnity
chromatography. His-bind resin was used according to the manufacturer’s
instructions (Novagen, Darmstead, Germany). Fractions containing the sialidase or
domains were dialysed against 2 4 l 10mM HEPES (pH 8.0) and concentrated
using a 10-kDa MWCO Vivaspin column (Vivaspin, Goettingen, Germany) up to
6mgml 1. The protein was further puriﬁed by gel ﬁltration using the Superdex
200 column on an Akta system (GE Health Care Life Sciences, Little Chalfont, UK).
Protein puriﬁcation was assessed by standard SDS–polyacrylamide gel
electrophoresis using the both the NuPAGE Novex 4–12% Bis-Tris (Life
Technologies, Paisley, UK) and RunBlue 12% SDS–polyacrylamide gel electrophoresis
gels (Expedeon, Cambridge, UK). Protein concentration was measured with a
NanoDrop (Thermo Scientiﬁc, Wilmington, USA) and using the extinction coefﬁcient
calculated by Protparam (ExPASy-Artimo, 2012) from the peptide sequence.
Activity assays and kinetics. The puriﬁed enzymes were incubated with the
substrate in buffer made from 20mM Na2HPO4 and 20mM NaH2PO4 adjusted to
pH 6.5 containing 1mgml 1 BSA at 37 C unless otherwise stated. For 4MU-
Neu5Ac, the progression of the reaction was monitored by the release of the MU
using a 96-well plate reader (BMG Labtech, Ortenberg, Germany) using ﬂuores-
cence with an excitation at 340 nm and an emission at 420 nm. For determining the
optimal temperature, the assay was carried out in 20mM PBS at pH 7.4. For
determining the optimal pH, the assay was carried out at 37 C using buffer made
from 20mM Na2HPO4 and 20mM NaH2PO4 in varying proportions to obtain the
desired pH. PNP release from PNP-Neu5Ac was monitored in a similar way
measuring absorbance at 405 nm every 60 s. For 30SL, the reaction was monitored
by HPAEC-PAD. An aliquot of the reaction was removed from the main reaction
volume at the reaction stopped by boiling for 20min, the enzyme was then
removed by centrifugation at 17,000g for 10min and ﬁltration with a 0.2-mm ﬁlter
(Millipore, Billerica, USA). The sugars were separated by HPAEC with an isocratic
gradient of 100mM NaOH and 100mM NaAC at 1mlmin 1 on a CarboPac PA1
protected with a guard column and detected using PAD on a Dionex ICS5000
system (Thermo Scientiﬁc, Hemel Hempstead, UK). The column was cleaned with
10ml of 500mM NaOH and 500mM NaAc, and the column was re-equilibrated
with 100mM NaOH and 100mM NaAc. An internal standard of fucose was used
to quantify the results.
For 4MU-Neu5Ac and 30SL, the rate of hydrolysis without enzyme was not
signiﬁcant, thus raw data were used. However, for pNP-Neu5Ac, the rate of
hydrolysis without enzyme was signiﬁcant, thus the rate with enzyme was corrected
by the subtraction of the rate without enzyme at each concentration of substrate.
For 30SL, the rate of reaction was calculated by plotting the amount of substrate
remaining over the course of450 % of the reaction using the following equation58:
kt ¼ ln S0½ = St½ ð Þ
Where k is kcat/KM enzyme concentration, t is time, [S0] and [St] are substrate
concentrations at time 0 and t, respectively.
Kinetic data were obtained from at least duplicate (usually triplicate)
experiments, and the kinetic parameters were calculated by ﬁtting the initial raw
data to the Michaelis–Menten equation using a nonlinear regression analysis
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programme (Prism 6, GraphPad, San Diego, USA), and error bars (s.e.m.)
are shown.
For speciﬁcity tests against sialylated oligosaccharides (1mM) and glycoproteins
(1mgml 1), 1 nM of enzyme was incubated with the substrate at 37 C, pH 6.5,
overnight. For inhibition studies, the enzyme and inhibitor were pre-incubated
together for 15min at 37 C and the reaction started by the addition of the
substrate, the IC50 values were determined using Prism 6.
NMR analysis. Extracts (400 ml) were mixed with 200ml of D2O and 20ml of a
solution of D2O containing 1mM of TSP (sodium 3-(trimethylsilyl)-propionate-
d4). Samples (500 ml) were transferred into a 5-mm NMR tube for spectral
acquisition. The 1H NMR spectra were recorded at 600MHz on a Bruker Avance
spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany) running Topspin
2.0 software, and were ﬁtted with a cryoprobe and a 60-slot autosampler. Each 1H
NMR spectrum was acquired with 128 scans, a spectral width of 8,012.8Hz, an
acquisition time of 2.04 s and a relaxation delay of 2.0 s. The ‘noesypr1d’
presaturation sequence was used to suppress the residual water signal with
a low-power selective irradiation at the water frequency during the recycle delay
and a mixing time of 100ms. Spectra were transformed with a 0.3-Hz line
broadening, manually phased, baseline corrected and referenced by setting the TSP
methyl signal to 0 p.p.m.
Protein production and crystallization. The RgNanH NI-domain (residues
237–723) was cloned into the pEHISTEV vector59 using the following primers:
forward 50-GATATCGGATCCAATATCTTTTATGCAGGAGATGC-30 , reverse
50-TGGTGCTCGAGTTTATGGTTGAACTTTCAGTTCATC-30 . The domain was
expressed and puriﬁed as described above but with the additional step of removal
of the 6-histidine afﬁnity tag by tobacco etch virus protease at a mass ratio of 1:50
overnight at 4 C. High-purity fractions were pooled and concentrated to
36mgml 1 for storage and crystallization trials.
All crystallization experiments were carried out at 20 C by the sitting drop,
vapour diffusion method. Initial conditions were screened by the high-throughput
Gryphon system (Art Robbins). Optimization was carried out manually with
extensive use of serial micro-seeding. The best conditions for N-domain
crystallization were as follows: 0.8M NaH2PO4, 1.2M K2HPO4 and 0.1M sodium
acetate (pH 4.5; condition 1); 1.2M NaH2PO4, 0.8 M K2HPO4 and 0.1M CAPS
(pH 10.5; condition 2); and 12.5% PEG 3350 and 200mM calcium chloride
(condition 3). Typically, the crystallization drop consisted of 1 ml protein solution
at 10–20mgml 1, 1 ml reservoir solution and 0.25 ml seed stock solution prepared
according to Bergfors and collaborators60. Crystals generally appeared after 48 h
and grew to full size in 72 h.
Ligand protein complexes were achieved by adding ligand stock solution in
H2O directly to the crystallization drop. The crystallization conditions and ﬁnal
ligand concentrations for the relevant complexes were as follows: 15mM
Neu5Ac2en for 20min in condition 1; 6mM siastatin B for 20min in condition 2;
and 10mM OC for 240min in condition 3. To achieve the 2,7-anhydro-Neu5Ac
complex, the crystals were soaked with 20mM 30SL for 30min in condition 1.
Crystals were cryoprotected by stroking the crystal, using a nylon loop, across the
top of a 1-ml drop containing the crystallization solution with 25% glycerol.
Structure determination and reﬁnement. Data were collected in-house at 100 K
on a Rigaku 007HFM rotating anode X-ray generator with a Saturn 944 CCD
detector at a wavelength of 1.54178Å. The data were processed with HKL2000
(ref. 61). The phase problem was solved by molecular replacement using
PHASER62 using the structure of NanL catalytic domain (PDB 2SLI) as a search
model. This was followed by manual rebuilding with COOT63 and reﬁnement
using REFMAC5 (ref. 64). The RgNanH–siastatin B made use of the Buccaneer
pipeline65. Ramachandran statistics in the form outliers (%)/favoured (%):
2,7-anhydro-Neu5Ac complex, 0.00/97.1; Neu5Ac2en complex 0.00/96.3; OC
complex, 0.00/96.5; and siastatin B, 0.41/95.9. For a stereo view of a portion of
electron density, see Supplementary Fig. 7. All molecular graphics were generated
with PYMOL66.
Genomic analysis of bacterial IT-sialidase. We searched for Nan clusters, sia-
lidase-encoding genes and other associated genes in 8,236 NCBI-distributed gen-
omes (ftp://ftp.ncbi.nlm.nih.gov) that had annotations of protein-coding sequences
and their products available (May 2014), as well as two additional R. gnavus
genomes23,67. These represent 8,126 unique strains of B2,800 species, comprising
28.6 million protein sequences. We used HMMER3 (http://hmmer.org) to query
pHMMs of the relevant protein domain sequences; for more details see
Supplementary Methods. Brieﬂy, we refer to the seven relevant protein domains as
follows: (i) NanA (R. gnavus NanA and homologues including B. fragilis NanL),
(ii) NanK (RgNanK and homologues), (iii) NanE1 (RgNanE and homologues
including E. coli NanE), (iv) NanE2 (B. fragilis NanE and homologues),
(v) ‘sialidase’ (the sialidase domain of RgNanH and homologues but excluding the
I-domain), (vi) I-domain (of RgNanH and homologues where present) and
(vii) CBM40 (of RgNanH and homologues where present). We used pHMMs from
Pfam68 when appropriate, but it was necessary to construct our own for (v and vi),
respectively, from 984 and 132 sequence segments from the GH33 family
(www.cazy.org). We also built our own model (vii) from 36 segments of these
sequences, although this performed very similarly to a Pfam pHMM; note that this
Pfam domain (PF02973) is named ‘sialidase’ but corresponds to CBM40, and not
to the actual sialidase domain (v). Note also that (v) detects conventional GH33
domains as a contiguous match as well as RgNanH-type domains as a segmented
match with a gap representing the location of the I-domain matched by (vi).
Having located the gene loci encoding the proteins matching our pHMMs, we
deﬁned gene clusters as cases of all genes of interest (NanA/K/E) being contained
within 15 consecutive loci (which may include intervening genes). In all cases, we
ignored all hits with an independent E-value of 410 4.
Metagenomic analysis of IT-sialidase prevalence. We analysed gut metage-
nomic data published by the MetaHIT consortium in a study of patients diagnosed
with IBD and a control group10. We translated the assembled coding sequences
(obtained from ftp://public.genomics.org.cn/BGI/gutmeta/SingleSample_
GenePrediction) of the metagenomes of the 125 human subjects (99 with no IBD
and 25 with IBD) described in Supplementary Table 1 of reference before searching
for pHMMs (v and vi) using HMMER3 as before. Further details are in the
Supplementary Information.
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